Pharma Vietnam at CPHI China 2026 — Vinphaco Advances Its Global Manufacturing and Export Strategy

Pharma Vietnam’s integration into global pharmaceutical supply chains took another concrete step forward in June 2026. From June 16 to 18, Vinphaco attended CPHI & PMEC China 2026 in Shanghai — one of Asia’s largest and most strategically significant pharmaceutical trade events, bringing together over 3,600 exhibiting companies and more than 110,000 industry professionals, procurement specialists, and supply chain decision-makers from across the global pharmaceutical industry. 

For international partners evaluating pharmaceutical contract manufacturing Vietnam capabilities, Vinphaco’s active participation in events of this scale is a direct signal: this is a manufacturer that understands the global landscape it operates in, and is actively building the supply chain relationships and technology capabilities that underpin long-term partnership reliability. 

 

1.CPHI China 2026 — The Global Pharmaceutical Industry in One Place 

CPHI & PMEC China is not simply a trade show. It is the primary annual convergence point for the Asian pharmaceutical manufacturing ecosystem — where raw material suppliers, equipment manufacturers, contract development and manufacturing organisations (CDMOs), finished goods producers, and international distributors meet to shape the supply chain relationships that will define the next 12 to 36 months of global pharmaceutical trade. 

The 2026 edition in Shanghai reflected the continued momentum of Asia’s pharmaceutical manufacturing sector — with particular focus on advanced manufacturing technology, API supply chain resilience, and the growing role of Southeast Asian manufacturers in diversifying global essential medicine supply away from single-source dependency. For pharma Vietnam companies like Vinphaco, this is precisely the environment in which to build the partnerships that accelerate international growth. Explore our Vietnamese domestic operations at vinphaco.vn. 

2. Vinphaco’s Strategic Objectives at CPHI China 2026 

Vinphaco’s delegation attended CPHI China 2026 with four defined strategic priorities, each directly linked to the company’s international development roadmap for 2026–2030. 

2.1. Advanced Manufacturing Technology Assessment 

Vinphaco used direct access to leading pharmaceutical equipment and technology suppliers at CPHI China to evaluate the latest advances in sterile manufacturing technology — including next-generation BFS (Blow-Fill-Seal) systems, enhanced Freeze-Drying (lyophilization) capabilities, and automated quality control integration. For international partners, this technology investment agenda signals a manufacturer actively upgrading the production infrastructure that supports export product quality and supply consistency. 

2.2. Raw Material, Excipient, and Packaging Supply Chain Expansion 

Product quality in pharmaceutical manufacturing is determined as much by input quality as by production process rigour. Vinphaco’s sourcing team at CPHI China engaged with international suppliers of active pharmaceutical ingredients, excipients, and primary packaging materials — expanding the supplier network that feeds our GMP-WHO certified production lines. Diversified, high-quality raw material sourcing directly reduces supply chain vulnerability and strengthens batch consistency for export markets. 

2.3. API and Finished Product Collaboration Opportunities 

Beyond sourcing, Vinphaco explored bilateral collaboration opportunities — both inbound raw material partnerships and outbound finished product supply arrangements — in a global pharmaceutical market actively restructuring its supply chains toward greater geographic diversification. This dual-direction engagement positions Vinphaco not merely as a buyer in the international pharmaceutical supply chain, but as a capable manufacturing and supply partner for companies seeking to reduce single-market production dependency. 

2.4. Export Partnership Development 

Expanding Vinphaco’s international distribution network is a primary strategic objective for 2026–2030. CPHI China provided direct access to importers, distributors, and drug registration partners across our target markets — particularly across Asia, where Vinphaco already maintains active supply relationships in 14+ countries, and in Middle East and African markets where our export presence is growing. Three days of direct engagement with qualified international counterparts at CPHI accelerates relationship development that would otherwise require months of remote outreach. 

3. What CPHI China Participation Signals to International Partners 

For pharmaceutical buyers and distribution partners evaluating a pharma Vietnam contract manufacturing relationship, trade event participation at the CPHI level carries specific due diligence value. It indicates that the manufacturer maintains current awareness of global pharmaceutical manufacturing standards and technology trends — that its quality systems and production capabilities are benchmarked against international peers, not isolated from them. 

Vinphaco’s presence at CPHI China 2026 — actively engaging with 3,600+ global pharmaceutical companies across three days — reflects the same outward orientation that has driven the company’s expansion to 24 export markets across Asia, Africa, and Oceania. A pharmaceutical contract manufacturing partner that invests in global industry engagement is one whose capabilities are tested against the best available international benchmarks. 

4. Pharma Vietnam’s Global Supply Chain Positioning — The 2026 Context 

Vietnam’s pharmaceutical sector is at an inflection point. With over 243 GMP-WHO certified manufacturing facilities, a national strategy targeting WHO Level 4 pharmaceutical manufacturing classification, and pharmaceutical exports reaching approximately USD 312 million in 2025, pharma Vietnam is transitioning from a regional supplier to a recognised participant in global pharmaceutical supply chains. 

The global pharmaceutical contract manufacturing market is projected to grow from USD 138 billion in 2023 to over USD 285 billion by 2032 — driven by increased outsourcing from innovator companies, rising demand for sterile injectables, and the accelerating need for supply chain geographic diversification. Vinphaco’s strategic positioning — GMP-WHO certified sterile manufacturing capability, proven multi-continent export track record, and active global partnership development — places it at the intersection of these growth drivers. 

5. After CPHI China 2026 — Converting Connections into Partnerships 

Three days in Shanghai mark the beginning, not the conclusion, of Vinphaco’s CPHI China 2026 outcomes. The supplier relationships, technology evaluations, and export partnership discussions initiated during the event will be developed into concrete collaboration agreements in the months ahead — feeding directly into Vinphaco’s 2026–2030 international development roadmap across supply chain optimisation, product portfolio expansion, and new market entry. 

For international buyers, distributors, and pharmaceutical partnership teams who met with Vinphaco at CPHI China 2026, or who are exploring a pharma Vietnam manufacturing relationship for the first time, we welcome the conversation. 

To discuss pharmaceutical contract manufacturing, raw material supply partnerships, private label pharmaceutical arrangements, or export distribution: vinphaco.net/contact | vinphaco.vn